Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311550 | 0.94 | SMN1; SMN2 (0.41) | TSHRNFKB1CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL9865161 | 0.75 | TSHR (0.44) | TSHRNFKB1CYP2C19 | |
| SCHEMBL986872 | 0.75 | TSHR (0.41) | TSHRNFKB1CYP2C19SMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9791511 | 0.74 | TSHR (0.41) | TSHRNFKB1CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL7743476 | 0.74 | TSHR (0.38) | TSHRNFKB1CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL11093396 | 0.74 | TSHR (0.38) | TSHRNFKB1CYP2C19 | |
| SCHEMBL4442630 | 0.73 | HDAC8 (0.34) | TSHRNFKB1CYP2C19ALDH1A1POLB | |
| SCHEMBL195275 | 0.72 | TSHR (0.37) | TSHRNFKB1CYP2C19 | |
| SCHEMBL6013597 | 0.72 | TSHR (0.37) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8308600 | 0.72 | TSHR (0.37) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197593-A1 | HYDROXYLAMINES AND DERIVATIVES FOR TREATMENT OF INFLAMMATORY CONDITIONS OF THE LIVER | COLBY PHARMACEUTICAL COMPANY | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197593-A1 | HYDROXYLAMINES AND DERIVATIVES FOR TREATMENT OF INFLAMMATORY CONDITIONS OF THE LIVER | HNMT, PYGL, HDGF | TSHR 2284/4885NFKB1 515/4885CYP2C19 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.